his.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Effects of Digitoxin and Pembrolizumab treatment on HepG2 cancer cell line
University of Skövde, School of Health and Education.
2019 (English)Independent thesis Basic level (degree of Bachelor), 20 credits / 30 HE creditsStudent thesis
Abstract [en]

Hepatocellular carcinoma (HCC) is the main disease affecting the liver and widely extended over the population, with a prevalence that has increased over the years. Several studies have shown the effect of digitoxin (a cardiac glycoside) and pembrolizumab (an immunotherapy antibody) in reducing the viability of cancer cells by promoting apoptosis and increasing the action of T-cells against them, respectively. In this project, a study was conducted in order to assess the effect of these two drugs on the HepG2 cancer cell line after 24, 48, and 72h of treatment. Different concentrations of the drugs were tested to identify the existence of any significant difference in the cell’s viability with 1, 5, 10, 25 and 100 nM of digitoxin and 0.5, 2, 10 and 50 mg/L of pembrolizumab and their combination. An MTS assay was performed as well as an Amplex-Red assay in order to measure the cell viability and the ROS (reactive oxygen species) levels. Finally, the expression of PD-1, PD-L1, and PD-L2, important genes for the tumor progression, was measured performing a RT-q-PCR. The results showed that certain concentrations of the drugs promoted a decrease in the cell viability, indeed, showing synergetic effects when combined. Moreover, the expression of the genes was confirmed, obtaining a significant variability depending on the treatment. Finally, ROS levels decreased after the treatment at specific concentrations.

Place, publisher, year, edition, pages
2019. , p. 42
Keywords [en]
Hepatocellular carcinoma, HepG2, Digitoxin, Pembrolizumab, cell viability, PD-1, PD-L1, PD-L2
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:his:diva-17745OAI: oai:DiVA.org:his-17745DiVA, id: diva2:1356591
Educational program
Biomedicine - Study Programme
Supervisors
Examiners
Available from: 2019-10-07 Created: 2019-10-01 Last updated: 2019-10-07Bibliographically approved

Open Access in DiVA

No full text in DiVA

Search in DiVA

By author/editor
Lozano Madueño, Cristina
By organisation
School of Health and Education
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 4 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf